摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(S)-tert-butyl 2-(hydroxymethyl)-2,5-dihydro-1H-pyrrole-1-carboxylate | 205444-34-4

中文名称
——
中文别名
——
英文名称
(S)-tert-butyl 2-(hydroxymethyl)-2,5-dihydro-1H-pyrrole-1-carboxylate
英文别名
(S)-N-tert-butoxycarbonyl-2-hydroxymethyl-2,5-dihydro-(1H)-pyrrole;(2S)-N-tert-butoxycarbonyl-2-hydroxymethyl-2,5-dihydro-1H-pyrrole;(2S)-N-(tert-Butoxycarbonyl)-2-hydroxymethyl-3-pyrroline;(2S)-N-tert-butyloxycarbonyl-2-hydroxymethyl-3-pyrroline;(S)-N-tert-butoxycarbonyl-2-hydroxymethyl-3-pyrroline;(S)-N-Boc-prolinol;tert-butyl (2S)-2-(hydroxymethyl)-2,5-dihydropyrrole-1-carboxylate
(S)-tert-butyl 2-(hydroxymethyl)-2,5-dihydro-1H-pyrrole-1-carboxylate化学式
CAS
205444-34-4
化学式
C10H17NO3
mdl
——
分子量
199.25
InChiKey
RJLZUQYWPYTGAB-QMMMGPOBSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    292.7±33.0 °C(Predicted)
  • 密度:
    1.114±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.7
  • 重原子数:
    14
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.7
  • 拓扑面积:
    49.8
  • 氢给体数:
    1
  • 氢受体数:
    3

安全信息

  • 危险性防范说明:
    P280,P305+P351+P338
  • 危险性描述:
    H302,H317
  • 储存条件:
    室温

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • A chiral phosphine–olefin ligand derived from l-hydroxyproline and its use in the rhodium-catalyzed asymmetric 1,4-addition
    作者:Vasudeva Rao Gandi、Yixin Lu、Tamio Hayashi
    DOI:10.1016/j.tetasy.2015.05.004
    日期:2015.7
    A new chiral phosphine–olefin ligand (S)-1 has been designed and synthesized from l-hydroxyproline via a short reaction sequence. It was examined for its efficiency in the rhodium-catalyzed asymmetric addition of arylboronic acids and a phenylzinc reagent to cyclic α,β-unsaturated ketones, giving 1,4-addition products with high enantioselectivities.
    一种新的手性膦配体的烯烃(小号) - 1已被设计,并通过短的反应序列从L-羟脯氨酸合成。它检查其在铑催化的不对称加成的芳基硼酸的效率和phenylzinc试剂环状α,β不饱和酮,得到1,4-加成产品具有高对映选择性。
  • [EN] BIOLOGICALLY ACTIVE COMPOUNDS<br/>[FR] COMPOSES A ACTIVITE BIOLOGIQUE
    申请人:AMURA THERAPEUTICS LTD
    公开号:WO2004007501A1
    公开(公告)日:2004-01-22
    Compounds of general formula (I) wherein: Z = CR3R4, where R3 and R4 are independently chosen from CO-7-alkyl P1 = CR5R6, P2 = O, CR7R8 or NR9, Y = CR10R11-C(O) or CR10R11-C(S) or CR10R11-S(O) or CR10R11-SO2 (X)o=.CR16R17 (W)n = 0, S, C(O), S(O) or S(O)2-or NR18 (V)m = C(O), C(S), S(O), S(O)2, S(O)2NH, OC(O), NHC(O), NHS(O), NHS(O)2, OC(O)NH, C(O)NH or CR19R20, C=N-C(O)-OR19 or C=N-C(O)-NHR19, U = a stable. 5- to 7-membered monocyclic or a stable 8- to 11-membered bicyclic ring which is either saturated or unsaturated, and which includes zero to four heteroatoms and their salts, hydrates, solvates, complexes and prodrugs are inhibitors of cathepsin K and other cysteine protease inhibitors and are useful as therapeutic agents, .for example in osteoporosis, Paget's disease gingival diseases such as gingivitis and periodontitis, hypercalaemia of malignancy, metabolic bone disease, diseases involving matrix or cartilage degradation, in particular osteoarthritis and rheumatoid arthritis and neoplastic diseases. The compounds are also useful for validating therapeutic target compounds.
    通式(I)的化合物中:其中:Z = CR3R4,其中R3和R4分别选择自CO-7-烷基P1 = CR5R6,P2 = O,CR7R8或NR9,Y = CR10R11-C(O)或CR10R11-C(S)或CR10R11-S(O)或CR10R11-SO2(X)o = .CR16R17(W)n = 0,S,C(O),S(O)或S(O)2-或NR18(V)m = C(O),C(S),S(O),S(O)2,S(O)2NH,OC(O),NHC(O),NHS(O),NHS(O)2,OC(O)NH,C(O)NH或CR19R20,C = N-C(O)-OR19或C = N-C(O)-NHR19,U = a stable。5-至7-成员单环或稳定的8-至11-成员双环,其饱和或不饱和,并包括零至四个杂原子及其盐、水合物、溶剂合物、络合物和前药是猫hepsin K和其他半胱氨酸蛋白酶抑制剂的抑制剂,并可用作治疗剂,例如在骨质疏松症、Paget病、牙龈疾病如牙龈炎和牙周炎、恶性高钙血症、代谢性骨病、涉及基质或软骨降解的疾病,特别是骨关节炎和类风湿性关节炎和肿瘤性疾病。这些化合物还可用于验证治疗靶点化合物。
  • cis-6-Oxo-hexahydro-2-oxa-1,4-diazapentalene and cis-6-oxo-hexahydropyrrolo[3,2-c]pyrazole based scaffolds: design rationale, synthesis and cysteinyl proteinase inhibition
    作者:Yikang Wang、Alex Benn、Nick Flinn、Tracy Monk、Manoj Ramjee、John Watts、Martin Quibell
    DOI:10.1016/j.bmcl.2005.01.022
    日期:2005.3
    The 5,5-bicycles cis-6-oxo-hexahydro-2-oxa-1,4-diazapentalene 3 and cis-6-oxo-hexahydropyrrolo[3,2-c]pyrazole 4 were designed as rotationally restricted templates towards the preparation of inhibitors of CAC1 cysteinyl proteinases. The design strategy was exemplified through the solution and solid phase preparation of potent inhibitors of human cathepsin K and may potentially be applied to inhibitors
    将5,5-二环顺式-6-氧代六氢-2-氧杂-1,4-二氮杂戊烯3和顺式-6-氧代六氢吡咯并[3,2-c]吡唑4设计为旋转受限的模板,用于制备CAC1半胱氨酸蛋白酶的抑制剂的制备。通过溶液和固相制备有效的人组织蛋白酶K抑制剂来举例说明该设计策略,并且可能将其应用于其他CAC1蛋白酶的抑制剂。
  • Novel Routes to the Kainates: Stereoselectivity in Addition Reactions to ­Pyrrole [1,2<i>c</i>]-oxazol-3-one
    作者:P. J. Parsons、A. J. Murray、E. S. Greenwood、E. M. Viseux
    DOI:10.1055/s-2004-829076
    日期:——
    This paper describes the addition of a range of electrophiles to 1. An unusual and unpredicted stereochemistry of addition has been observed in line with our original photochemical observations.
    本文描述了一系列亲电体与 1 的加成反应。根据我们最初的光化学观察,我们发现了一种不寻常的、未曾预料到的加成立体化学现象。
  • Intramolecular 5-<i>endo</i>-trig aminopalladation of β-hydroxy-γ-alkenylamine: efficient route to a pyrrolidine ring and its application for the synthesis of (−)-8,8a-di-<i>epi</i>-swainsonine
    作者:Priyanka Singh、Gautam Panda
    DOI:10.1039/c3ra45409f
    日期:——
    The intramolecular aminopalladation reaction of L-serine derived β-hydroxy-γ-alkenylamines undergoes 5-endo-trig cyclization to furnish pyrrolidine rings in high yields. The pyrrolidines thus obtained were used in the synthesis of ()-8,8a-di-epi-swainsonine, a specific and competitive inhibitor (Ki value 2 × 10−6 M) of lysosomal α-mannosidases.
    L-丝氨酸衍生的β-羟基-γ-链烯基胺的分子内氨基palpalation反应经过5-内切-trig环化反应以高产率提供吡咯烷环。如此获得的吡咯烷用于合成(-)-8,8a-di-表-swainsonine,一种特异性和竞争性的溶酶体α-甘露糖苷酶抑制剂(Ki值2×10 -6 M)。
查看更多

同类化合物

颜料红254 颜料橙73 颜料橙 71 赛拉霉素 裂假丝菌素 苯扎托品氢溴酸盐 苯乙醇,2-(甲氧基甲基)-(9CI) 细交链孢菌酮酸 禾大壮 甲基4-甲酰基-2,3-二氢-1H-吡咯-1-羧酸酯 甲基4-甲氧基-2,5-二氧代-2,5-二氢-1H-吡咯-3-羧酸酯 甲基3,4-二溴-2,5-二氧代-2H-吡咯-1(5H)-羧酸叔丁酯 甲基2-氮杂双环[3.2.0]庚-3,6-二烯-2-羧酸酯 甲基1-甲基-2,5-二氢-1H-吡咯-3-羧酸酯 甲基(3R)-3-羟基-3,4-二氢-2H-吡咯-5-羧酸酯 烯丙基2,3-二氢-1H-吡咯-1-羧酸酯 氯化烯丙基(3-氯-2-羟基丙基)二甲基铵 氨基甲酰基-2,2,5,5-四甲基-3-吡咯啉-1-氧基 氟酰亚胺 异丙基3,4-二氢-2H-吡咯-5-羧酸酯 己二酸,聚合1,3-二异氰酸基甲基苯,1,2-乙二醇,甲基噁丙环并,噁丙环和1,2-丙二醇 四琥珀酰亚胺金(3+)钾盐 四丁基铵琥珀酰亚胺 吡啶氧杂胺 吡啶,2-[4-(4-氟苯基)-3,4-二氢-2H-吡咯-5-基]- 吡咯烷-2,4-二酮 吡咯布洛芬 叔丁基4-溴-2-氧代-2,5-二氢-1H-吡咯-1-甲酸叔丁酯 叔丁基1H,2H,3H,4H,5H,6H-吡咯并[3,4-C]吡咯-2-甲酸酯盐酸盐 叔-丁基4-(4-氯苯基)-2-氧亚基-2,5-二氢-1H-吡咯-1-甲酸基酯 利收 假白榄内酰胺 二氯马来酸的N-(间甲基苯基)酰亚胺 二-硫代-二(N-苯基马来酰亚胺) 乙基4-羟基-1-[(4-甲氧苯基)甲基]-5-羰基-2-(3-吡啶基)-2H-吡咯-3-羧酸酯 乙基2-氧代-3,4-二氢-2H-吡咯-5-羧酸酯 乙基2,5-二氢-1H-吡咯-3-羧酸酯 乙基1-苄基-4-羟基-5-氧代-2,5-二氢-1H-吡咯-3-羧酸酯 β.-核-六吡喃糖,1,6-脱水-2-O-(2-氰基苯基)甲基-3-脱氧-4-O-甲基- [4-(2,5-二氧代吡咯-1-基)苯基]乙酸酯 [3-乙酰基-2-(4-氟-苯基)-4-羟基-5-氧代-2,5-二氢-吡咯-1-基]-乙酸 [3-(甲氧羰基)-2,2,5,5-四甲基-2,5-二氢-1H-吡咯-1-基]氧氮自由基 [3,4-二(溴甲基)-2,2,5,5-四甲基-2,5-二氢-1H-吡咯-1-基]氧氮自由基 [(2R)-1-乙酰基-2,5-二氢-1H-吡咯-2-基]乙腈 S,S'-[(1-羟基-2,2,5,5-四甲基-2,5-二氢-1H-吡咯-3,4-二基)二(亚甲基)]二甲烷硫代磺酸酯 N-重氮基-4-(2,5-二氧代吡咯-1-基)苯磺酰胺 N-苯基马来酰亚胺 N-甲氧基羰基顺丁烯二酰亚胺 N-甲基-4-羟基-5-氧代-3-吡咯啉-3-羧酸乙酯铁螯合物 N-氨基甲酰马来酰亚胺